Advancements in genetic profiling have led to the growth of targeted therapies, such as FLT3 inhibitors (e.g., midostaurin, gilteritinib) and IDH inhibitors (e.g., ivosidenib, enasidenib), which have shown efficacy in treating AML with specific mutations [5,6]. This evidence concerns the gene IDH1 and acute myeloid leukemia.